Unwanted disorders and xenogeneic graft-versus-host disease in experimental immunodeficient mice: How to evaluate and how to report

Abstract

Human-derived tumor models are essential for preclinical development of new anticancer drug entities. Generating animal models bearing tumors of human origin, such as patient-derived or cell line–derived xenograft tumors, is dependent on immunodeficient strains. Tumor-bearing immunodeficient mice are susceptible to developing unwanted disorders primarily irrelevant to the tumor nature; and if get involved with such disorders, reliability of the study results will be undermined, inevitably confounding the research in general. Therefore, a rigorous health surveillance and clinical monitoring system, along with the establishment of a strictly controlled barrier facility to maintain a pathogen-free state, are mandatory. Even if all pathogen control and biosafety measures are followed, there are various noninfectious disorders capable of causing tissue and multiorgan damage in immunodeficient animals. Therefore, the researchers should be aware of sentinel signs to carefully monitor and impartially report them. This re discusses clinical signs of common unwanted disorders in experimental immunodeficient mice, and how to examine and report them.

Keywords

animal models / graft-versus-host disease / health surveillance / preclinical drug evaluation / xenograft model antitumor assays

References

[1] Muhammadnejad S, Monzavi SM, Khorsand AA, Kajbafzadeh AM. PDX clinical trial design in Anti-Cancer Research. In: Rahman A, ed. Rahman A, editor. Topics in Anti-Cancer Research: Volume 10. Bentham Science; 2021:100-150.

[2] Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20(1):206.

[3] Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):160.

[4] Zeng M, Ruan Z, Tang J, et al. Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice. Cancer Cell Int. 2023;23(1):120.

[5] Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. Blood. 2015;125(17):2630-2640.

[6] Bak I, Kim DJ, Kim HC, et al. Two base pair deletion in IL2 receptor gamma gene in NOD/SCID mice induces a highly severe immunodeficiency. Lab Anim Res. 2020;36:27.

[7] Zhang M, Guo C, Shen Y, Guo Y. The B-NDG mouse is a perfect tool for immune system humanization and patient derived xenograft transplantation. Cancer Res. 2018;78(13_Suppl):1157.

[8] Gutierrez-Barbosa H, Medina-Moreno S, Perdomo-Celis F, et al. A comparison of lymphoid and myeloid cells derived from human hematopoietic stem cells xenografted into NOD-derived mouse strains. Microorganisms. 2023;11(6):1548.

[9] Chen J, Liao S, Xiao Z, et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front Immunol. 2022;13:1007579.

[10] Burkholder T, Foltz C, Karlsson E, Linton CG, Smith JM. Health evaluation of experimental laboratory mice. Curr Protoc Mouse Biol. 2012;2:145-165.

[11] Akhtar A. The flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 2015;24(4):407-419.

[12] Morton LD, Sanders M, Reagan WJ, Crabbs TA, McVean M, Funk KA. Confounding factors in the interpretation of preclinical studies. Int J Toxicol. 2019;38(3):228-234.

[13] Baker DG. Natural pathogens of laboratory mice, rats, and rabbits and their effects on research. Clin Microbiol Rev. 1998;11(2):231-266.

[14] Fahey JR, Olekszak H. An overview of typical infections of research mice: health monitoring and prevention of infection. Curr Protoc Mouse Biol. 2015;5(3):235-245.

[15] Leung C, Chijioke O, Gujer C, et al. Infectious diseases in humanized mice. Eur J Immunol. 2013;43(9):2246-2254.

[16] Nicklas W, Bleich A, Mähler M. Viral infections of laboratory mice. In: Hedrich HJ, ed. The Laboratory Mouse. 2nd ed. Academic Press, Elsevier; 2012:427-480.

[17] Pritchett-Corning KR, Cosentino J, Clifford CB. Contemporary prevalence of infectious agents in laboratory mice and rats. Lab Anim. 2009;43(2):165-173.

[18] Pritchett-Corning KR, Clifford CB. Parasitic infections of laboratory mice. In: Hedrich HJ, ed. The Laboratory Mouse. Academic Press, Elsevier; 2012:503-518.

[19] Clifford CB, Pritchett-Corning KR. Bacterial infections of laboratory mice. In: Hedrich HJ, ed. The Laboratory Mouse. Academic Press, Elsevier; 2012:481-501.

[20] Buchheister S, Bleich A. Health monitoring of laboratory rodent colonies-talking about (r)evolution. Animals (Basel). 2021;11(5):1410.

[21] Baker DG, Lipman NS. Factors that can influence animal research. In: Fox JG, Anderson LC, Otto GM, Pritchett-Corning KR. Whary MT, eds. Laboratory Animal Medicine. Academic Press; 2015:1441-1496.

[22] Schiffer SP. Animal welfare and colony management in cancer research. Breast Cancer Res Treat. 1997;46(2-3):313-331.

[23] Brayton C. Spontaneous diseases in commonly used mouse strains. In: Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL, eds. The Mouse in Biomedical Research. Academic Press; 2007:623-717.

[24] Moyer AM, Yu J, Sinnwell JP, et al. Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. Oncotarget. 2019;10(39):3924-3930.

[25] Murphy ED. Characteristic tumors. In: Green EL, ed. Biology of the Laboratory Mouse. Dover; 1975:521-562.

[26] Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-1146.

[27] Flurkey K, Currer JM, Leiter EH, Witham B. The Jackson Laboratory Handbook on Genetically Standardized Mice. 6th ed. The Jackson Laboratory; 2009.

[28] Yasuda M, Ogura T, Goto T, et al. Incidence of spontaneous lymphomas in non-experimental NOD/Shi-scid, IL-2Rgamma(null) (NOG) mice. Exp Anim. 2017;66(4):425-435.

[29] Chateau-Joubert S, Hopfe M, Richon S, et al. Spontaneous mouse lymphoma in patient-derived tumor xenografts: the importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials. Transl Oncol. 2021;14(8):101133.

[30] Cardiff RD, Anver MR, Boivin GP, et al. Precancer in mice: animal models used to understand, prevent, and treat human precancers. Toxicol Pathol. 2006;34(6):699-707.

[31] Ward JM. Preneoplastic and precancerous lesions in rodents: morphologic and molecular characteristics. J Toxicol Pathol. 2002;15(2):123-128.

[32] Chiu PP, Ivakine E, Mortin-Toth S, Danska JS. Susceptibility to lymphoid neoplasia in immunodeficient strains of nonobese diabetic mice. Cancer Res. 2002;62(20):5828-5834.

[33] Tillman H, Janke LJ, Funk A, Vogel P, Rehg JE. Morphologic and immunohistochemical characterization of spontaneous lymphoma/leukemia in NSG mice. Vet Pathol. 2020;57(1):160-171.

[34] Lairmore MD, Niewiesk S. Models of virus-induced carcinogenesis and oncolytic viruses. ILAR J. 2016;57(1):1-2.

[35] Avdoshina DV, Kondrashova AS, Belikova MG, Bayurova EO. Murine models of chronic viral infections and associated cancers. Mol Biol. 2022;56(5):649-667.

[36] Panfil AR, Al-Saleem JJ, Green PL. Animal models utilized in HTLV-1 research. Virology (Auckl). 2013;4:49-59.

[37] Nakajima S, Okuma K. Mouse models for HTLV-1 infection and adult T cell leukemia. Int J Mol Sci. 2023;24(14):11737.

[38] Ahmed EH, Baiocchi RA. Murine models of Epstein-Barr virus-associated lymphomagenesis. ILAR J. 2016;57(1):55-62.

[39] Tillman H, Vogel P, Rogers T, Akers W, Rehg JE. Spectrum of posttransplant lymphoproliferations in NSG mice and their association with EBV infection after engraftment of pediatric solid tumors. Vet Pathol. 2020;57(3):445-456.

[40] Lange PT, Damania B. Modeling oncogenic herpesvirus infections in humanized mice. Curr Opin Virol. 2020;44:90-96.

[41] Milicevic NM, Nohroudi K, Milicevic Z, Hedrich HJ, Westermann J. T cells are required for the peripheral phase of B-cell maturation. Immunology. 2005;116(3):308-317.

[42] Lu R, Wu S, Zhang Y, et al. HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice. AIDS Res Hum Retrovir. 2014;30(7):677-684.

[43] Wunderlich M, Brooks RA, Panchal R, Rhyasen GW, Danet-Desnoyers G, Mulloy JC. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood. 2014;123(24):e134-e144.

[44] Monzavi SM, Muhammadnejad A, Behfar M, Khorsand AA, Muhammadnejad S, Kajbafzadeh AM. Spontaneous xenogeneic GvHD in Wilms’ tumor patient-derived xenograft models and potential solutions. Animal Model Exp Med. 2022;5(4):389-396.

[45] Radaelli E, Hermans E, Omodho L, et al. Spontaneous post-transplant disorders in NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) mice engrafted with patient-derived metastatic melanomas. PLoS One. 2015;10(5):e0124974.

[46] Naserian S, Leclerc M, Thiolat A, et al. Simple, reproducible, and efficient clinical grading system for murine models of acute graft-versus-host disease. Front Immunol. 2018;9:10.

[47] Holguin L, Echavarria L, Burnett JC. Novel humanized peripheral blood mononuclear cell mouse model with delayed onset of graft-versus-host disease for preclinical HIV research. J Virol. 2022;96(3):e0139421.

[48] Muhammadnejad S, Monzavi SM, Torabi-Rahvar M, et al. Efficacy of adoptively transferred allogeneic CIK cells on colorectal cancer: augmentative antitumoral effects of GvHD. Int Immunopharmacol. 2023;114:109446.

[49] Fried JH, Worth DB, Brice AK, Hankenson FC. Type, duration, and incidence of pathologic findings after retroorbital bleeding of mice by experienced and novice personnel. J Am Assoc Lab Anim Sci. 2015;54(3):317-327.

[50] Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50(5):600-613.

[51] Bartholomew PM, Kreeger JM, Morton D. Injection-site malignant fibrous histiocytomas in a pegvisomant carcinogenicity study in SD rats. Toxicol Pathol. 2014;42(7):1082-1091.

[52] Abu Hejleh T, Clamon GH. Extravasation. In: Perry MC, Doll DC, Freter CE, eds. Perry’s the Chemotherapy Source Book. 5th ed. Lippincott Williams & Wilkins; 2012:155-159.

[53] Buetow BS, Chen LI, Maggio-Price L, Swisshelm K. Peritonitis in nude mice in a xenograft study. Contemp Top Lab Anim Sci. 1999;38(6):47-49.

[54] Leinonen H, Tanila H. Vision in laboratory rodents-tools to measure it and implications for behavioral research. Behav Brain Res. 2018;352:172-182.

[55] Finesso G, Willis E, Tarrant JC, et al. Spontaneous early-onset neurodegeneration in the brainstem and spinal cord of NSG, NOG, and NXG mice. Vet Pathol. 2023;60(3):374-383.

[56] Goto T. Patient-derived tumor xenograft models: toward the establishment of precision cancer medicine. J Pers Med. 2020;10(3):64.

[57] Katano I, Ito R, Eto T, Aiso S, Ito M. Immunodeficient NOD-scid IL-2Rgamma(null) mice do not display T and B cell leakiness. Exp Anim. 2011;60(2):181-186.

[58] Whitehead JC, Hildebrand BA, Sun M, et al. A clinical frailty index in aging mice: comparisons with frailty index data in humans. J Gerontol A Biol Sci Med Sci. 2014;69(6):621-632.

[59] Wilkinson MJ, Selman C, McLaughlin L, et al. Progressing the care, husbandry and management of ageing mice used in scientific studies. Lab Anim. 2020;54(3):225-238.

[60] Pettan-Brewer C, Treuting PM. Practical pathology of aging mice. Pathobiol Aging Age Relat Dis. 2011;1(1):7202.

[61] Donnelly TM, Walberg J. Enlarged mouse preputial glands. Lab Anim (NY). 2011;40(3):69-71.

[62] Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555-1577.

[63] Spangenberg EM, Keeling LJ. Assessing the welfare of laboratory mice in their home environment using animal-based measures—a benchmarking tool. Lab Anim. 2016;50(1):30-38.

[64] Fentener van Vlissingen JM, Borrens M, Girod A, Lelovas P, Morrison F, Torres YS. The reporting of clinical signs in laboratory animals: FELASA Working Group Report. Lab Anim. 2015;49(4):267-283.

[65] Ullman-Culleré MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49(3):319-323.

[66] Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148-154.

[67] Ramasawmy R, Johnson SP, Roberts TA, et al. Monitoring the growth of an orthotopic tumour xenograft model: multi-modal imaging assessment with benchtop MRI (1T), high-field MRI (9.4T), ultrasound and bioluminescence. PLoS One. 2016;11(5):e0156162.

[68] Rojas JD, Joiner JB, Velasco B, et al. Validation of a combined ultrasound and bioluminescence imaging system with magnetic resonance imaging in orthotopic pancreatic murine tumors. Sci Rep. 2022;12(1):102.

[69] Rose A. Six Strategies for Success Caring for Immunodeficient Mice. The Jackson Laboratory; 2016. Accessed June 14, 2024. https://www.jax.org/news-and-insights/jax-blog/2016/august/6-strategies-for-success-caring-for-immuno-deficient-mic

[70] Committee on the Use of Live Animals in Teaching and Research. CULATR Guidelines for the Welfare and Use of Animals in Cancer Research. The University of Hong Kong; 2020. Accessed June 14, 2024. https://www.med.hku.hk/-/media/HKU-Med-Fac/research/ethics/animal/culatr/policy-and-guidelines/Welfare-and-Use-of-Animals-in-Cancer-Research-Policy_M45_1120_20210115.pdf

[71] Fernando N, Kung CJS. Guidelines for Procedures Involving Tumour Induction in Rodents. Animal Experimentation Ethics Committee in The Chinese University of Hong Kong; 2022. Accessed June 14, 2024. https://aeec.cuhk.edu.hk/uploads/1/3/8/0/138048846/20220318_tumorguidelines.pdf

[72] Foltz CJ, Ullman-Cullere M. Guidelines for assessing the health and condition of mice. Lab Anim (NY). 1999;28(4):28-32.

[73] Campos-Luna I, Miller A, Beard A, Leach M. Validation of mouse welfare indicators: a Delphi consultation survey. Sci Rep. 2019;9(1):10249.

[74] Peus D, Newcomb N, Hofer S. Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak. 2013;13:72.

[75] Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002-2007.

[76] Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.

[77] Marshall LJ, Bailey J, sotta M, Herrmann K, Pistollato F. Poor translatability of biomedical research using animals—a narrative review. Altern Lab Anim. 2023;51(2):102-135.

[78] Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114-118.

[79] Mirzayans R, Murray D. What are the reasons for continuing failures in cancer therapy? Are misleading/inappropriate preclinical assays to Be blamed? Might some modern therapies cause more harm than benefit? Int J Mol Sci. 2022;23(21):13217.

[80] Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med. 2018;16(1):304.

[81] Green SB. Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research. BMC Med Ethics. 2015;16:53.

[82] Check HE. Misleading mouse studies waste medical resources. Nature. 2014;507:14938.

[83] Hartung T. The (misleading) role of animal models in drug development. Front Drug Discov (Lausanne). 2024;4:1355044.

[84] Verlaat L, Riesner K, Kalupa M, et al. Novel pre-clinical mouse models for chronic graft-versus-host disease. Front Immunol. 2022;13:1079921.

[85] Moretto MM, Lawlor EM, Khan IA. Aging mice exhibit a functional defect in mucosal dendritic cell response against an intracellular pathogen. J Immunol. 2008;181(11):7977-7984.

[86] Jackson SJ, Andrews N, Ball D, et al. Does age matter? The impact of rodent age on study outcomes. Lab Anim. 2017;51(2):160-169.

[87] Hu JG, Yokoyama T, Kitagawa T. Studies on the optimal immunization schedule of experimental animals. IV. The optimal age and sex of mice, and the influence of booster injections. Chem Pharm Bull(Tokyo). 1990;38(2):448-451.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.